Bridge­Bio eyes US fil­ing for AT­TR-CM drug af­ter new PhI­II da­ta show ‘fastest’ clin­i­cal ben­e­fit to date

Bridge­Bio is prepar­ing to sub­mit an FDA fil­ing for its transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM) drug can­di­date, dubbed aco­ramidis, be­fore the end of the year af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER